MedTrace Logo

Bawei Shenqi Pill in the Treatment of Ankylosing Spondylitis

NCT04480359 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-08-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether Bawei Shenqi Pill is effective in the treatment of active ankylosing spondylitis (AS).

Conditions

Interventions

DRUG

Bawei Shenqi Pill

5.1g, once a day, 3month, oral

DRUG

Bawei Shenqi Pill placebo

5.1g, once a day, 3month, oral

DRUG

Meloxicam

7.5mg, once a day, 3 month, oral

Sponsors & Collaborators

  • Shanghai University of Traditional Chinese Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2020-08-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04480359 on ClinicalTrials.gov